Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NYSE:ADCT NASDAQ:CRBU OTCMKTS:ETST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.21-0.9%$2.41$1.19▼$3.60$161.07M0.34651,879 shs200,245 shsADCTADC Therapeutics$1.23-3.5%$1.81$0.78▼$4.98$161.53M1.871.40 million shs787,039 shsCRBUCaribou Biosciences$1.66+0.6%$1.87$1.38▼$3.54$163.65M2.362.57 million shs1.02 million shsETSTEarth Science Tech$0.15+7.1%$0.17$0.00▼$0.24$40.26M2.4153,457 shs11,550 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+0.90%-11.86%-1.33%-20.64%+43.87%ADCTADC Therapeutics+0.79%+3.24%+17.51%-68.78%-59.39%CRBUCaribou Biosciences+1.85%-5.71%+0.92%-30.08%-20.29%ETSTEarth Science Tech+0.07%-11.39%-20.45%-3.45%-22.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.21-0.9%$2.41$1.19▼$3.60$161.07M0.34651,879 shs200,245 shsADCTADC Therapeutics$1.23-3.5%$1.81$0.78▼$4.98$161.53M1.871.40 million shs787,039 shsCRBUCaribou Biosciences$1.66+0.6%$1.87$1.38▼$3.54$163.65M2.362.57 million shs1.02 million shsETSTEarth Science Tech$0.15+7.1%$0.17$0.00▼$0.24$40.26M2.4153,457 shs11,550 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+0.90%-11.86%-1.33%-20.64%+43.87%ADCTADC Therapeutics+0.79%+3.24%+17.51%-68.78%-59.39%CRBUCaribou Biosciences+1.85%-5.71%+0.92%-30.08%-20.29%ETSTEarth Science Tech+0.07%-11.39%-20.45%-3.45%-22.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.33Hold$8.00261.99% UpsideADCTADC Therapeutics 2.33Hold$6.25410.20% UpsideCRBUCaribou Biosciences 2.75Moderate Buy$8.67422.09% UpsideETSTEarth Science Tech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ETST, CRBU, ADCT, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ADCTADC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026CRBUCaribou Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026ABOSAcumen Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/8/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/4/2026ADCTADC Therapeutics StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$5.006/4/2026ADCTADC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$6.00 ➝ $2.005/11/2026CRBUCaribou Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.005/5/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.005/5/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$1.16 per shareN/AADCTADC Therapeutics$81.36M1.92N/AN/A($1.50) per share-0.82CRBUCaribou Biosciences$11.16M14.75N/AN/A$1.31 per share1.27ETSTEarth Science Tech$35.70M1.21$0.01 per share10.42$0.02 per share7.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$121.33M-$1.86N/AN/AN/AN/A-123.07%-79.41%8/11/2026 (Estimated)ADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%8/11/2026 (Estimated)CRBUCaribou Biosciences-$148.12M-$1.42N/AN/AN/A-1,189.14%-84.17%-60.51%8/11/2026 (Estimated)ETSTEarth Science Tech$3.63MN/AN/A15.00N/A10.11%65.02%43.09%8/14/2026 (Estimated)Latest ETST, CRBU, ADCT, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ABOSAcumen Pharmaceuticals-$0.39N/AN/AN/AN/AN/A8/11/2026Q2 2026ADCTADC Therapeutics-$0.19N/AN/AN/A$18.89 millionN/A8/11/2026Q2 2026CRBUCaribou Biosciences-$0.33N/AN/AN/A$2.28 millionN/A6/18/2026Q4 2026ETSTEarth Science Tech$0.01$0.01N/AN/A$8.91 million$9.50 million5/12/2026Q1 2026ABOSAcumen Pharmaceuticals-$0.4028-$0.33+$0.0728-$0.33N/AN/A5/7/2026Q1 2026CRBUCaribou Biosciences-$0.33-$0.26+$0.07-$0.26$2.21 million$2.40 million5/4/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AADCTADC TherapeuticsN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.194.554.55ADCTADC TherapeuticsN/A4.094.02CRBUCaribou BiosciencesN/A6.226.22ETSTEarth Science TechN/A1.931.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ADCTADC Therapeutics41.10%CRBUCaribou Biosciences77.51%ETSTEarth Science TechN/AInsider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals10.20%ADCTADC Therapeutics5.40%CRBUCaribou Biosciences8.54%ETSTEarth Science Tech24.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2072.23 million64.86 millionOptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableCRBUCaribou Biosciences10099.18 million90.71 millionOptionableETSTEarth Science Tech3287.59 million215.98 millionNot OptionableETST, CRBU, ADCT, and ABOS HeadlinesRecent News About These CompaniesEarth Science Tech (ETST) Delivers Strong Fiscal Year as Healthcare Businesses Turn Cash-Flow PositiveJuly 16, 2026 | markets.businessinsider.comEarth Science Tech (ETST) Leveraging Technology and Strategic Positioning to Advance the Industry and Stamp Its Market PositionJuly 16, 2026 | markets.businessinsider.comEarth Science Tech (ETST) Presents Fiscal Year-End Financial Results for March 31, 2026, Operating a Diversified Holding Company ModelJune 28, 2026 | markets.businessinsider.comETST increasing revenue and improving marginsJune 20, 2026 | msn.comEarth Science Tech (ETST) Positioned at Intersection of Telemedicine, Pharmacy, Healthcare ServicesJune 18, 2026 | markets.businessinsider.comEarth Science Tech, Inc. Reports Fiscal Year-End Financial Results for March 31, 2026June 18, 2026 | globenewswire.comEarth Science Tech (ETST) Reports Transformational Fiscal Year as Share Repurchases and Healthcare Expansion Shape Growth StrategyJune 17, 2026 | markets.businessinsider.comEarth Science Tech (OTC: ETST) Highlights Fiscal 2026 Growth and Cash Flow Progress in Shareholder LetterJune 10, 2026 | markets.businessinsider.comEarth Science Tech, Inc. (ETST) Annual Shareholder Letter for FY Ended March 31, 2026June 10, 2026 | globenewswire.comEarth Science Tech (OTC: ETST) CEO to Present at Planet MicroCap Las Vegas 2026 ConferenceJune 4, 2026 | markets.businessinsider.comEarth Science Tech, Inc. (ETST) to Present at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClubJune 3, 2026 | globenewswire.comEarth Science Tech, Inc. (ETST) Launches MyOnlineConsultation.com, Finalizing a Fully Vertically Integrated Telehealth and Pharmacy EcosystemMarch 24, 2026 | globenewswire.comETST: F2Q26 earnings review – increasing visibility into accelerating growth and stronger financial performanceFebruary 18, 2026 | msn.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Giorgio R. Saumat, CEO of Earth Science Tech Inc.February 17, 2026 | markets.businessinsider.comEarth Science Tech, Inc. Announces Initiatives to Advance Public Company Strategy; Expects Approximately $1.4 Million in Annualized Savings and Fiscal 2026 Net Income Growth of ...February 17, 2026 | manilatimes.netMEarth Science Tech, Inc. (ETST) Reports Third Fiscal Quarter 2026 ResultsFebruary 17, 2026 | markets.businessinsider.comEarth Science Tech, Inc. Announces Initiatives to Advance Public Company Strategy; Expects Approximately $1.4 Million in Annualized Savings and Fiscal 2026 Net Income Growth of More Than 40%, from $3.3 Million to $4.7 MillionFebruary 17, 2026 | globenewswire.comEarth Science Tech, Inc. (ETST) Upgrades Audit Capabilities, Engages Semple, Marchal & Cooper, LLP as Independent PCAOB Auditor to Support Continued ExpansionFebruary 17, 2026 | globenewswire.comEarth Science Tech, Inc. (ETST), to Report Financial Results for Fiscal Third Quarter on February 17, 2026February 9, 2026 | globenewswire.comJapan hauls rare earth-rich mud from deep sea in bold test missionFebruary 4, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETST, CRBU, ADCT, and ABOS Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.21 -0.02 (-0.90%) Closing price 04:00 PM EasternExtended Trading$2.22 +0.00 (+0.23%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.ADC Therapeutics NYSE:ADCT$1.23 -0.05 (-3.54%) Closing price 03:59 PM EasternExtended Trading$1.23 0.00 (0.00%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Caribou Biosciences NASDAQ:CRBU$1.66 +0.01 (+0.61%) Closing price 04:00 PM EasternExtended Trading$1.65 -0.01 (-0.48%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Earth Science Tech OTCMKTS:ETST$0.15 +0.01 (+7.14%) As of 03:57 PM EasternEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Boxabl Disrupts Housing With A Tiny Float IPO Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
